DexCom price target raised to $115 from $110 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on DexCom to $115 from $110 and keeps an Equal Weight rating on the shares. The company beat sales and earnings expectations for Q1 and raised guide, but was overshadowed by last week’s 50% growth reported by its key competitor, the analyst tells investors in a research note. However, the firm believes the initial pressure on the stock post-results may be overdone.